| Abstract | S obzirom da novije studije ukazuju da izraženost CD44 u tumorima ima prognostičku
vrijednost, cilj ovog istraživanja bio je imunohistokemijski odrediti izraženost CD44 u
glioblastomu te ispitati njegovu korelaciju s gustoćom novostvorenih krvnih žila i
preživljenjem bolesnika. U istraživanju je uključeno 55 bolesnika s glioblastomima - 26
(47,3%) žena i 29 (52,7%) muškaraca, prosječne dobi 62,58 godina (od 47 do 77). Korišteno je
primarno protutijelo na CD44 (razrjeđenje 1:50) i primarno protutijelo na endoglin (CD105)
(razrjeđenje 1:250). Imunohistokemijska analiza učinjena je LSAB metodom na DAKO
TechMate TM automatiziranom stroju uz upotrebu streptavidin imunoperoksidaza MSIP
protokola. Rezultati analize CD44 su prikazani semikvantitativno, a gustoća novostvorenih
tumorskih krvnih žila (MVD) mjerena je u području najaktivnije neovaskularizacije tumora.
Učinjena je statistička analiza rezultata prema dobi bolesnika, duljini preživljenja, CD44,
MVD/CD105 i Karnofsky Score-u. Prosječni Karnofsky score bolesnika je iznosio 75,45, a
prosječno preživljenja bolesnika 183,82 dana. Dobiveni prosječni CD44 je iznosio 64,91 (od
40,00 do 90,00), a prosječni MVD/CD105 15,64 (od 3,67 do 52,33). Statističkom analizom je
utvrđena negativna korelacija između CD44 i preživljenja (P=0,023)(veća ekspresija CD44
korelirala je s kraćim preživljenjem) te pozitivna korelacija između Karnofsky score-a i
preživljenja (P=0,018)(veći Karnofsky score je korelirao s duljim preživljenjem). Značajni
individualni prediktori za dulje preživljenje bili su niža ekspresija CD44 (P=0,004), veći
Karnofsky score (P=0,045), te ženski spol (P=0,017). Dobiveni rezultati mogli bi ukazati na
ulogu CD44 u progresiji i tumorskoj neovaskularizaciji glioblastoma, te na njegovo
prognostičko značenje, što bi se eventualno moglo iskoristiti u razvoju specifične molekularne
terapije. |
| Parallel abstract (English) | Considering that the new studies are showing that the expression of CD44 in tumors has a
prognostic value, the purpose of this research was to immunohistochemically determine
expression of CD44 in glioblastoma, and to question its correlation with the density of newly –
created blood weasels and survival of the patient. Research was conducted on fifty – five
patients with glioblastoma; 26 women (47,3%) and 29 men (52,7%) of average year 62,58
(from 47 do 77). Primary antibody on CD44 (sparse 1:50) and primary antibody on endoglin
(CD105) (sparse 1:250) were used. Immunohistocemical analysis was performed with LSAB
method on DAKO TechMate TM automatized machine with the use of streptovidin
immunoperoxidation MSIP protocol. The results of the analysis were semi – quantitatively
shown, and the density of the newly – created blood weasels (MVD) was measured in the most
active area of neovascularization of tumor. Statistic analysis of the results was conducted
according to the age of patient, length of survival, CD44, MVD/CD105 and Karnofsky Score.
The average Karnofsky Score of the patient was 75, 45%, and the average survival of the
patient were 183, 82 days. The results of average CD44 was 64, 91 (from 40, 00 to 90, 00), and
the average MVD/CD105 – 15, 64 (from 3, 67 to 52, 33). Statistic analysis determined
negative correlation between CD44 and the survival (P=0, 023) (bigger expression of CD44
was correlated with the shorter survival), and also positive correlation between Karnofsky
Score and the survival (P=0, 018) (bigger Karnofsky Score was correlated with longer
survival). The significant individual predictors for longer survival were lower expression of
CD44 (P=0, 004), higher Karnofsky Score (P=0, 045), and female gender (P=0, 017). The
given results could show the role of CD44 in a progression and tumor neovascularization of
glioblastoma, and on its prognostic value, which could be eventually used in the development
of specific molecular therapy. |
